Blog
RSS FeedPosted by Michael Wonder on 08 Apr 2024
Australians benefit from cheaper medicines on the PBS
8 April 2024 - Australians with high cholesterol, chronic kidney disease and ovarian cancer now have access to cheaper medicines under ...
Posted by Michael Wonder on 02 Apr 2024
BMS’ oral plaque psoriasis drug Sotyktu gets reimbursement starting April
1 April 2024 - Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate to severe plaque psoriasis in adults, ...
Posted by Michael Wonder on 31 Mar 2024
Schedule of Pharmaceutical Benefits - 1 April 2024
1 April 2024 - The April 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Mar 2024
New Zealand Pharmaceutical Schedule - 1 April 2024
1 April 2024 - The April 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Mar 2024
PHARMAC funds new treatments for breast and blood cancer
27 March 2024 - PHARMAC is funding two new cancer treatments, one for advanced breast cancer (ribociclib succinate) and one ...
Posted by Michael Wonder on 29 Feb 2024
Schedule of Pharmaceutical Benefits - 1 March 2024
1 March 2024 - The March 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 03 Feb 2024
Pfizer's Bosulif for leukaemia gains insurance coverage, patients urge inclusion for children, first-line use
3 January 2024 - Pfizer's second generation targeted therapy for chronic myeloid leukaemia, Bosulif (bosutinib), has been newly registered with ...
Posted by Michael Wonder on 31 Jan 2024
New Zealand Pharmaceutical Schedule - 1 February 2024
1 February 2024 - The February 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Jan 2024
Schedule of Pharmaceutical Benefits - 1 February 2024
1 February 2024 - The February 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 23 Jan 2024
PHARMAC - 2023 in review (Part 2)
23 January 2024 - This week, we have reviewed the listing of innovative (patent protected) health care technologies in the ...
Posted by Michael Wonder on 21 Jan 2024
Advanced melanoma treatment to be added to Pharmaceutical Benefits Scheme
21 January 2024 - Treatment for advanced melanoma is set to become cheaper under the Pharmaceutical Benefits Scheme in the ...
Posted by Michael Wonder on 17 Jan 2024
PBAC - 2023 in review
18 January 2024 - In contrast to New Zealand, 2023 saw many new medicines listed on the PBS. ...
Posted by Michael Wonder on 16 Jan 2024
PHARMAC - 2023 in review
17 January 2024 - 2023 was yet another dismal year for New Zealanders in terms of them being able to ...
Posted by Michael Wonder on 16 Jan 2024
Ono Pharm’s Braftovi for BRAF V600E mutated colorectal cancer gets reimbursement
11 January 2024 - Ono Pharmaceutical Korea said Thursday that Braftovi (encorafenib), a targeted therapy for BRAF V600E mutated metastatic ...
Posted by Michael Wonder on 08 Jan 2024
'GSK's immunotherapy Jemperli paves way for second-line endometrial cancer treatment'
7 December 2023 - GSK's immunotherapy Jemperli (dostarlimab) is set to play a key role in the second-line treatment of ...